


VERSION WITH MARKINGS TO SHOW CHANGES MADE TO SPECIFICATION

The paragraphs at page 95 have been amended as follows:

ABSTRACT

The present invention provides a cyclic peptide or salt having [a cyclic structure and having] the activity to restore [the] activities of native P53 protein to mutant P53 protein[, and a pharmaceutically acceptable salt thereof, said]. The peptide [being] is represented by [general] formula (I):



[([)wherein [any of]  $X^1$  to  $X^{17}$  [may be denoted by  $X^i$  and  $n1$  to  $n17$  may be denoted by  $X^i$  and  $n_i$ , respectively ( $i$  stands for an integer of 1 to 17);  $X^i$ ] independently represent[s] an amino acid residue, an organic acid residue or a bond with the proviso that at least 7  $X^i$ 's are not bonds, and a functional group in [residue  $X^p$  ( $p$  is an integer of 1 to 11) selected from the group] of  $X^1$  to  $X^{11}$  and a functional group in [residue  $X^q$  ( $q$  is an integer of 8 to 17, provided that  $q$  is larger than  $p$ ) selected from the group of]  $X^8$  to  $X^{17}$  together form a cyclic structure [(] where the cross-linkage in the cyclic structure is [selected from] S-S, S-CH<sub>2</sub>-S, S-CH<sub>2</sub>-C<sub>6</sub>H<sub>4</sub>-CH<sub>2</sub>-S, S-CH<sub>2</sub>-CO, CO-NH, NH-CO, O-CO [and] or CO-O bond[s);  $R^1$  represents substituted or unsubstituted alkanoyl, etc.; and  $R^2$  represents substituted or unsubstituted alkoxy, etc.}].